2Q EARNINGS: AbbVie ups profit target as Humira sales surge
This article was originally published in Scrip
Executive Summary
AbbVie’s blockbuster drug Humira continues to show strong growth and helped the company beat Wall Street expectations for second-quarter profit. AbbVie also increased a target for full-year earnings.